NICE TAs

23/04/2020

TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

23/04/2020

TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

23/04/2020

TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

23/04/2020

TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

23/04/2020

TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

23/04/2020

TA551: Lenvatinib for untreated advanced hepatocellular carcinoma

22/04/2020

TA575: Tildrakizumab for treating moderate to severe plaque psoriasis

22/04/2020

TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis

22/04/2020

TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

22/04/2020

TA556: Darvadstrocel for treating complex perianal fistulas in Crohn's disease

22/04/2020

TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

22/04/2020

TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

22/04/2020

TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema

22/04/2020

TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia

22/04/2020

TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

22/04/2020

TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)

22/04/2020

TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast

22/04/2020

TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

22/04/2020

TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

22/04/2020

TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer